<DOC>
	<DOCNO>NCT02421016</DOCNO>
	<brief_summary>The bioresorbable polymer SYNERGY EES exhibit favourable vascular heal profile patient undergo coronary intervention de novo lesion . Specifically , SYNERGY EES superior ABSORB bioresorbable vascular scaffold term antirestenotic efficacy assess angiography 6-8 month .</brief_summary>
	<brief_title>Test Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone ( ISAR-RESORB )</brief_title>
	<detailed_description>Percutaneous coronary intervention ( PCI ) drug-eluting stent ( DES ) implantation currently represent dominant treatment strategy patient undergoing catheter intervention . However , effective neointimal suppression occur cost systematic delay arterial heal comparison bare metal stenting . This underlie small significant increase risk stent thrombosis DES implantation comparison bare metal stent implantation well possible excess in-stent neoatheroma formation . To address issue recent technological advance focus bioresorbable polymer coating development stent fully resorbable backbone . Newer generation metallic DES bioresorbable polymer coating show improve vascular heal coronary stenting . In particular novel thin-strut bioresorbable polymer everolimus-eluting stent ( EES , SYNERGY , Boston Scientific Corp. , Natick , MA , USA ) show high angiographic antirestenotic efficacy well high clinical efficacy safety early randomize trial . In addition , DES bioresorbable backbone represent alternative approach ensure short-term vessel scaffold drug delivery enhance vessel heal . The everolimus-eluting bioresorbable backbone stent ( ABSORB bioresorbable vascular scaffold [ BVS ] , Abbott Vascular , Santa Rosa , CA , USA ) most-extensively studied device class early report select patient show encouraging clinical result . However requirement thicker stent strut careful lesion preparation lead concern potential clinical benefit may offset erosion early antirestenotic efficacy occurrence clinical event related limitation device deployment . At present lack randomize clinical trial data examine outcomes patient treat two alternative strategy . The aim current ISAR-RESORB study test clinical performance bioresorbable-polymer SYNERGY ABSORB BVS patient undergo PCI de novo coronary lesion . The primary endpoint percentage diameter stenosis protocol-mandated 6-8 month angiographic follow-up . Secondary clinical endpoint assess 12 month . Sample size calculation base superiority hypothesis SYNERGY versus ABSORB BVS . It plan enrol total 230 patient .</detailed_description>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients 18 year old ischemic symptom evidence myocardial ischemia presence ≥ 50 % de novo stenosis locate native coronary vessel ( max . 2 lesion 2 separate vessel ) Reference diameter ≥2.5 mm ≤3.9 mm Lesion length &lt; 28 mm Written , inform consent patient participation study Cardiogenic shock Acute STelevation myocardial infarction within 48 hour symptom onset . Target lesion locate leave main trunk bypass graft Severe calcification lesion Target lesion contain side branch ( diameter ≥2mm ) bifurcation locate 2 mm away bifurcation Ostial lesion Severe vessel tortuosity Renal insufficiency ( recent serum creatinine within last 72h prior randomization &gt; 2 mg/dl 177 µmol/l ) Malignancies comorbid condition life expectancy le 12 month may result protocol noncompliance Pregnancy , present ( positive pregnancy test ) , suspect plan , breast feeding Contraindications allergy platinum , chromium , everolimus inability take antiplatelet therapy least 6 month stenting ; know allergy PLLA , PDLLA PLGA polymer Previous enrollment trial Patient 's inability fully cooperate study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>De novo stenosis</keyword>
	<keyword>bioresorbable polymer coating</keyword>
	<keyword>bioresorbable polymer backbone</keyword>
</DOC>